Fibrosis Clinical Trial
Official title:
A Multi-Cohort, Randomised, Placebo-Controlled Phase 2a Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Ascending Doses of RXC007 in Patients With Idiopathic Pulmonary Fibrosis
The purpose of the study is to assess the safety and tolerability of RXC007 when given for 12 weeks (84 days), alone and in combination with nintedanib or pirfenidone.
The purpose of this study is to investigate the study drug RXC007. The main objectives of this study are as follows: - To determine the safety and tolerability (degree to which side effects of a drug can be tolerated) of RXC007 when it is administered as twice daily doses over a period of up to 12 weeks (84 days). - To investigate the concentration of RXC007 (how much drug is in your blood), how this changes over a period of time and to evaluate whether there are differences in the concentration between different dose strengths of RXC007. - To investigate the effect of RXC007 on the body (known as pharmacodynamics) by analysing the levels of certain biomarkers in the body and to assess the effect of RXC007 on markers associated with Idiopathic Pulmonary Fibrosis (IPF). Biomarkers are markers within the body such as a molecule or compound made by cells in the body, which can be measured and used to identify a particular disease. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03979417 -
Identification of Biomarkers Related to Liver Fibrosis as New Therapeutic Targets
|
||
| Completed |
NCT02408744 -
Utility of Prolonged-release Pirfenidone in the Progression of Chronic Kidney Disease
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT00148837 -
Efficacy of Prazosin Versus Placebo Associated With Peg-Interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe Fibrosis
|
Phase 2 | |
| Recruiting |
NCT05661123 -
Effect of Modified Complete Decongestive Therapy on Lower Limbs Fibrosis Post Cellulitis
|
N/A | |
| Recruiting |
NCT04795570 -
Urethral Stricture After Transurethral Resection of the Prostate/Bladder: a Prospective Study of Risk Factors
|
||
| Active, not recruiting |
NCT05075785 -
Covid-19 Respiratory Sequelae French Cohort
|
||
| Recruiting |
NCT03308916 -
Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers
|
N/A | |
| Recruiting |
NCT05459259 -
Physiotherapy for Arthrofibrosis Following Knee Replacement.
|
||
| Enrolling by invitation |
NCT01483248 -
Human Menstrual Blood-derived Mesenchymal Stem Cells for Patients With Liver Cirrhosis
|
Phase 1/Phase 2 | |
| Completed |
NCT00001729 -
Combination Drug Therapy for Patients With Hepatitis C
|
Phase 3 | |
| Completed |
NCT02049307 -
Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Trial
|
Phase 2 | |
| Active, not recruiting |
NCT05685823 -
The Impact of Conventional Hemodialysis and Renal Transplantation on the Global Longitudinal Strain of the Left Ventricle
|
||
| Completed |
NCT00744939 -
Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist
|
Phase 4 | |
| Completed |
NCT00252642 -
Peginterferon Alpha-2a Maintenance Therapy for Portal Hypertension in Patients With Hepatitis C
|
N/A | |
| Recruiting |
NCT04934202 -
Cohort Follow-up of Survivors of Hospitalization for COVID-19 During the 2nd Wave of the Epidemic in France
|
||
| Completed |
NCT02774161 -
B-mode Ultrasound Imaging in Detecting Early Liver Cancer
|
N/A | |
| Completed |
NCT02604862 -
Imaging FIB ONE in the Human Lung Using Endomicroscopy
|
Early Phase 1 | |
| Active, not recruiting |
NCT01246388 -
Non-Invasive Evaluation of Fibrosis and Steatosis in Chronic Hepatopathy
|
N/A | |
| Completed |
NCT00347009 -
Adefovir Dipivoxil For The Treatment Of Patients With Chronic Hepatitis B Related Advanced Fibrosis Or Cirrhosis
|
Phase 4 | |
| Completed |
NCT02161952 -
Pirfenidone, an Antifibrotic and Antiinflammatory Drug
|
Phase 2 |